We assessed real-world efficacy of SOF plus RBV with or without IFN in these difficult-to-treat patients with chronic hepatitis C. Our study demonstrated that SOF-based regimens can result in high overall SVR rates, similar to SVR rates achieved in clinical trials [11, 12]. The gene discussed is IFNA1; the disease is chronic hepatitis C virus infection.